Geron Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

Country	United States
Founded	1990
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	141
CEO	John Scarlett

Contact Details

Address: 919 East Hillsdale Boulevard Foster City, Delaware 94404 United States
Phone	650 473 7700
Website	geron.com

Stock Details

Ticker Symbol	0IV3
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US3741631036
SIC Code	2836

Key Executives

Name	Position
Dr. John A. Scarlett M.D.	Chairman of the Board, President and Chief Executive Officer
Michelle J. Robertson	Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer
Dr. Andrew J. Grethlein Ph.D.	Executive Vice President and Chief Operating Officer
Scott Samuels	Executive Vice President, Chief Legal Officer and Secretary
Aron Feingold	Vice President of Investor Relations and Corporate Communications
Shannon T. Odam	Senior Vice President and Chief People Officer
Melissa A. Kelly Behrs	Executive Vice President of Business Operations and Chief Alliance Officer
Edward E. Koval	Executive Vice President and Chief Business Officer
Dr. Faye Feller M.D.	Executive Vice President and Chief Medical Officer
James Ziegler M.B.A.	Executive Vice President and Chief Commercial Officer